GW&K Investment Management LLC Boosts Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

GW&K Investment Management LLC boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,382,441 shares of the specialty pharmaceutical company's stock after buying an additional 176,091 shares during the period. GW&K Investment Management LLC owned approximately 2.48% of Supernus Pharmaceuticals worth $45,275,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of SUPN. Proficio Capital Partners LLC bought a new position in Supernus Pharmaceuticals in the fourth quarter valued at $408,000. Raymond James Financial Inc. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter worth about $6,847,000. HighTower Advisors LLC raised its stake in Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares in the last quarter. Swiss National Bank raised its stake in Supernus Pharmaceuticals by 0.7% in the 4th quarter. Swiss National Bank now owns 108,400 shares of the specialty pharmaceutical company's stock worth $3,920,000 after purchasing an additional 800 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of Supernus Pharmaceuticals by 18.5% in the 4th quarter. Teacher Retirement System of Texas now owns 16,331 shares of the specialty pharmaceutical company's stock valued at $591,000 after buying an additional 2,544 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN traded up $0.89 during trading on Monday, reaching $33.23. The stock had a trading volume of 869,764 shares, compared to its average volume of 493,944. The firm's fifty day moving average is $32.41 and its 200 day moving average is $33.62. Supernus Pharmaceuticals, Inc. has a 52 week low of $27.05 and a 52 week high of $40.28. The stock has a market cap of $1.86 billion, a price-to-earnings ratio of 14.70 and a beta of 0.70.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Sunday.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.